Usefulness of Non TNF Usage in RA Patients | NCT03784261 | Trialant

Usefulness of Non TNF Usage in RA Patients | NCT03784261 | Trialant

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
SAR, usually subucutaneous injection every 2 weeks	Active Comparator		Drug: Drug: "Salirumab" Drug: Drug: "Tocilizmab" Drug: Drug: "Abatacept"
TCZ, usually subucutaneous injection every 2 weeks	Active Comparator		Drug: Drug: "Salirumab" Drug: Drug: "Tocilizmab" Drug: Drug: "Abatacept"
ABT, usually subucutaneous injection every week	Active Comparator		Drug: Drug: "Salirumab" Drug: Drug: "Tocilizmab" Drug: Drug: "Abatacept"

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Drug: "Salirumab"	Drug	To examine the effects of salirumab in RA patients	ABT, usually subucutaneous injection every week SAR, usually subucutaneous injection every 2 weeks

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change from Baseline Values of DAS28-CRP	Assessment of efficacy in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).	Baseline and 1 year
Assessment of adverse event in rheumatoid arthritis patients for 1 year treated by salirumab (N=30), tocilizumab (N=30), or abatacept (N=30).		at 1 year

Condition Browse Module

Intervention Browse Module